These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22018193)

  • 1. Safety of glucocorticoids - clinical trials.
    Da Silva JA
    Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S99-103. PubMed ID: 22018193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years.
    Santiago T; da Silva JA
    Ann N Y Acad Sci; 2014 May; 1318():41-9. PubMed ID: 24814757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice.
    van der Goes MC; Jacobs JW; Boers M; Andrews T; Blom-Bakkers MA; Buttgereit F; Caeyers N; Cutolo M; Da Silva JA; Guillevin L; Kirwan JR; Rovensky J; Severijns G; Webber S; Westhovens R; Bijlsma JW
    Ann Rheum Dis; 2010 Nov; 69(11):1913-9. PubMed ID: 20693273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epidemiology of glucocorticoid-associated adverse events.
    McDonough AK; Curtis JR; Saag KG
    Curr Opin Rheumatol; 2008 Mar; 20(2):131-7. PubMed ID: 18349741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of low-dose glucocorticoids in rheumatic diseases: results from observational studies.
    Hwang YG; Saag K
    Neuroimmunomodulation; 2015; 22(1-2):72-82. PubMed ID: 25228230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of low-dose glucocorticoids in rheumatic diseases.
    Hwang YG; Saag K
    Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S104-12. PubMed ID: 22018194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose glucocorticoids in early rheumatoid arthritis.
    Strand V; Simon LS
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S186-90. PubMed ID: 14969074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glucocorticoids in rheumatic diseases - what is the optimal dose?].
    Krause D
    Dtsch Med Wochenschr; 2012 Sep; 137(36):1751-4. PubMed ID: 22933199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
    Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developments in glucocorticoid therapy.
    Bijlsma JW; Saag KG; Buttgereit F; da Silva JA
    Rheum Dis Clin North Am; 2005 Feb; 31(1):1-17, vii. PubMed ID: 15639052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward safer treatment with glucocorticoids: via patient and rheumatologist perspectives to recommendations on monitoring for adverse events.
    van der Goes MC; Jacobs JW; Bijlsma JW
    Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S116-20. PubMed ID: 22018196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of glucocorticoids in rheumatoid arthritis: evidence from recent clinical trials.
    Santiago T; da Silva JA
    Neuroimmunomodulation; 2015; 22(1-2):57-65. PubMed ID: 25228045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial.
    Hoes JN; Jacobs JW; Hulsmans HM; De Nijs RN; Lems WF; Bruyn GA; Geusens PP; Bijlsma JW
    Clin Exp Rheumatol; 2010; 28(3):354-9. PubMed ID: 20406615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the toxicity of low-dose glucocorticoids: risks and fears.
    Da Silva JA; Jacobs JW; Bijlsma JW
    Ann N Y Acad Sci; 2006 Jun; 1069():275-88. PubMed ID: 16855155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid-related cardiovascular and cerebrovascular events in rheumatic diseases: myth or reality?
    Gonzalez-Gay MA
    Arthritis Rheum; 2007 Mar; 57(2):191-2. PubMed ID: 17330291
    [No Abstract]   [Full Text] [Related]  

  • 16. Quantifying risks: the case between glucocorticoids and tuberculosis.
    Carmona L
    Arthritis Rheum; 2006 Feb; 55(1):1-2. PubMed ID: 16463392
    [No Abstract]   [Full Text] [Related]  

  • 17. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases.
    Duru N; van der Goes MC; Jacobs JW; Andrews T; Boers M; Buttgereit F; Caeyers N; Cutolo M; Halliday S; Da Silva JA; Kirwan JR; Ray D; Rovensky J; Severijns G; Westhovens R; Bijlsma JW
    Ann Rheum Dis; 2013 Dec; 72(12):1905-13. PubMed ID: 23873876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials.
    Cheng J; Zhang X; Zhang W; He Q; Tao X; Chen J
    Am J Nephrol; 2009; 30(4):315-22. PubMed ID: 19546530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.
    Abadie EC; Devogealer JP; Ringe JD; Ethgen DJ; Bouvenot GM; Kreutz G; Laslop A; Orloff JJ; Vanderauwera PM; Delmas PD; Dere WH; Branco J; Altman RD; Avouac BP; Menkes CJ; Vanhaelst L; Mitlak BH; Tsouderos Y; Reginster JY
    Semin Arthritis Rheum; 2005 Aug; 35(1):1-4. PubMed ID: 16084217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative glucocorticoids in hip and knee surgery - benefit vs. harm? A review of randomized clinical trials.
    Lunn TH; Kehlet H
    Acta Anaesthesiol Scand; 2013 Aug; 57(7):823-34. PubMed ID: 23581549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.